Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-DFO-MSTP2109A PET Imaging in Prostate Cancer
NCT01774071Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2013
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 89Zr-DFO-MSTP2109A in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2013; status: completed.
02
Drugs
89Zr-DFO-MSTP2109A
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01774071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01774071.